Voyager Therapeutics (VYGR) Cash from Operations Growth (1y) (2015 - 2026)
Analysis
Voyager Therapeutics (VYGR) Cash from Operations Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 41.84% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 9.83% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -58.33% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | -24.59% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 97.11% |
| 10 | Voyager Therapeutics | 215.07 Mn | 98.73 Mn | - | 22.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.31% |
| Mar 31, 2026 | 11.81% |
| Dec 31, 2025 | -108.29% |
| Sep 30, 2025 | -11.01% |
| Jun 30, 2025 | -5.32% |
| Mar 31, 2025 | -164.48% |
| Dec 31, 2024 | 38.85% |
| Sep 30, 2024 | -32.86% |
| Jun 30, 2024 | -3,682.04% |
| Mar 31, 2024 | -52.44% |
| Dec 31, 2023 | -94.05% |
| Sep 30, 2023 | -29.90% |
| Jun 30, 2023 | 95.48% |
| Mar 31, 2023 | 258.93% |
| Dec 31, 2022 | -209.37% |
| Sep 30, 2022 | 21.74% |
| Jun 30, 2022 | 18.63% |
| Mar 31, 2022 | 261.67% |
| Dec 31, 2021 | 150.94% |
| Sep 30, 2021 | 16.29% |